At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GLUE Monte Rosa Therapeutics
Market Closed 10-02 16:00:00 EDT
10.50
-0.76
-6.75%
盘后10.55
+0.05+0.48%
19:56 EDT
High11.40Low10.32Vol2.21M
Open11.40D1 Closing11.26Amplitude9.59%
Mkt Cap895.79MTradable Cap572.00MTotal Shares85.31M
T/O23.57MT/O Rate4.07%Tradable Shares54.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win
Simply Wall St.  ·  10-03 14:24
Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win
Monte Rosa Grants Inducement Equity Awards to New Hires, Including Options for 86,725 Shares at $11.26
Reuters  ·  10-03 04:01
Monte Rosa Grants Inducement Equity Awards to New Hires, Including Options for 86,725 Shares at $11.26
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)
TIPRANKS  ·  10-02 22:00
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)
Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TIPRANKS  ·  10-02 20:55
Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)
Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
TIPRANKS  ·  10-02 19:15
Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)
TIPRANKS  ·  10-02 19:15
Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment
Dow Jones  ·  10-01 20:25
Monte Rosa Therapeutics Sees Positive Trial Results for Cardiovascular Disease Treatment
Monte Rosa Therapeutics, - to Initiate Multiple Phase 2 Studies of Mrt-8102 in High Unmet Need Indications
THOMSON REUTERS  ·  10-01 19:00
Monte Rosa Therapeutics, - to Initiate Multiple Phase 2 Studies of Mrt-8102 in High Unmet Need Indications
Monte Rosa Therapeutics Announces Positive Results for Mrt-8102 in Gforce-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of Ascvd in Subjects with Elevated CVD Risk
THOMSON REUTERS  ·  10-01 19:00
Monte Rosa Therapeutics Announces Positive Results for Mrt-8102 in Gforce-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of Ascvd in Subjects with Elevated CVD Risk
Monte Rosa Shares Gain Ahead of Clinical Trial Review
Dow Jones  ·  10-01 18:31
Monte Rosa Shares Gain Ahead of Clinical Trial Review
Monte Rosa Therapeutics Shares up 18% Premarket After H.c. Wainwright Initiates Coverage with Buy Rating
THOMSON REUTERS  ·  10-01 18:25
Monte Rosa Therapeutics Shares up 18% Premarket After H.c. Wainwright Initiates Coverage with Buy Rating
Monte Rosa Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $25
THOMSON REUTERS  ·  10-01 18:08
Monte Rosa Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $25
Monte Rosa to Present Phase 1 Gforce-1 Data for MRT-8102 in Elevated Cardiovascular Risk Subjects
Reuters  ·  10-01
Monte Rosa to Present Phase 1 Gforce-1 Data for MRT-8102 in Elevated Cardiovascular Risk Subjects
Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush
Dow Jones  ·  09-09
Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush
Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE
TIPRANKS  ·  09-09
Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
MT Newswires Live  ·  09-08
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
TIPRANKS  ·  09-08
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone
Reuters  ·  09-08
Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)
Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160
THOMSON REUTERS  ·  09-08
Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160

Introduction

Company Name.
Monte Rosa Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Issue price:
--